|Table of Contents|

Differential molecular typing of ductal carcinoma in situ,ductal carcinoma in situ with microinvasion and invasive ductal carcinoma of breast

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 01
Page:
69-75
Research Field:
Publishing date:

Info

Title:
Differential molecular typing of ductal carcinoma in situ,ductal carcinoma in situ with microinvasion and invasive ductal carcinoma of breast
Author(s):
LI Hongen; LYU Peifeng; XIE Hanmin; LI Yuelong; ZENG Yihui; MEI Shiwei
Department of Radiology,Guangdong Province Hospital for Women and Children Healthcare,Guangdong Guangzhou 511400,China.
Keywords:
ductal carcinoma in situ of breast; ductal carcinoma in situ of breast with microinvasion; invasive ductal carcinoma; clinicopathological features; molecular typing
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.01.012
Abstract:
Objective:To investigate the clinicopathologic features and molecular types of ductal carcinoma in situ (DCIS),ductal carcinoma in situ with microinfiltration (DCIS-MI) and invasive ductal carcinoma (IDC) of breast.Methods:Retrospective analysis was performed on patients with breast cancer diagnosed by menstrual pathology in our hospital from January 2015 to June 2022.Clinicopathologic data were analyzed,including patient age,estrogen receptor (ER),progesterone receptor (PR),human epidermal growth factor receptor-2 (HER-2),marker of tumor cell proliferation activity (Ki-67),and molecular typing.χ2 test or Fisher's exact probability method were used to compare the differences in clinicopathologic findings among the three groups.Results:A total of 1 167 patients were selected in this study,including 180 cases (15.42%) in the DCIS group,67 cases (5.74%) in the DCIS-MI group,and 920 cases (78.83%) in the IDC group.There were significant differences in the positive distribution and molecular typing of ER,PR,HER-2 and Ki-67 in patients with DCIS,DCIS-MI and IDC,with statistical significance (P＜0.05).Patients with DCIS-MI were mostly HER-2 overexpression type,ER and PR were mostly negative,and HER-2 was mostly positive,with high nuclear grading.Luminal A was the main type in DCIS patients,and Ki-67 was low expression.High nuclear grade,HER-2 overexpression,ER negative and PR negative are predictive factors that affect and promote the progression of breast DCIS to DCIS-MI.Most IDC patients were Luminal B type,with positive ER and PR status and high expression of Ki-67.There was no significant difference in age distribution (P＞0.05).Conclusion:The distribution of immunohistochemical markers and molecular typing among DCIS,DCIS-MI and IDC in breast is different.Compared with DCIS,the nuclear atypia of DCIS-MI is mostly of high nuclear grade,with more negative ER and PR,and more HER-2 overexpression type.Considering that DCIS-MI is an independent lesion,it has "qualitative" changes compared with DCIS.It suggests that the two are at different stages of breast cancer progression.

References:

［1］ PEREZ AA,BALABRAM D,ROCHA RM,et al.Co-expression of p16,ki67 and cox-2 is associated with basal phenotype in high-grade ductal carcinoma in situ of the breast［J］.The Journal of Histochemistry and Cytochemistry,2015,63(6):408-416.
［2］ VAN SEIJEN MAARTJE,LIPS ESTHER H，THOMPSON ALASTAIR M,et al.Ductal carcinoma in situ:to treat or not to treat,that is the question［J］.The British Journal of Cancer,2019,121(4):285-292.
［3］ SI W,LI T,HAN Y,et al.Epidemiological and clinicopathological trends of breast cancer in Chinese patients during 1993 to 2013:A retrospective study［J］.Medicine,2015,94(26):e820.
［4］ KHALIQ W,UZOARU I,KONCHANIN RP,et al.Solitary extramedullary plasmacytoma of the bladder:a case report and literature［J］.Oncology,2010,24(9):832-835.
［5］ GIULIANO ARMANDO E,CONNOLLY JAMES L,EDGE STEPHEN B,et al.Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual［J］.CA:A Cancer Journal for Clinicians,2017,67(4):290-303.
［6］ PHANTANA-ANGKOOL A,VOCI AMY E,WARREN YANCEY E,et al.Ductal carcinoma in situ with microinvasion on core biopsy:evaluating tumor upstaging rate,lymph node metastasis rate,and associated predictive variables［J］.Annals of Surgical Oncology,2019,26(12):3874-3882.
［7］ SOPIK VICTORIA,SUN PING,NAROD STEVEN A.Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ［J］.Breast Cancer Research and Treatment,2018,167(3):787-795.
［8］ MA XJ,SALUNGA R,TUGGLE JT,et al.Gene expression profiles of human breast cancer progression［J］.Proceedings of the National Academy of Sciences of the United States of America,2003,100(10):5974-5979.
［9］ CHAMPION CD,REN Y,THOMAS SM,et al.DCIS with microinvasion:is it in situ or invasive disease［J］.Annals of Surgical Oncology,2019,26(10):3124-3132.
［10］ YU KD,WU LM,LIU GY,et al.Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS),DCIS with microinvasion,and DCIS with invasion component［J］.Ann Surg Oncol，2011,18(5):1342-1348.
［11］ 王卓,吴祺,宁宁,等.mDixon-Quant技术在乳腺浸润性导管癌诊断与预后评估中的价值研究［J］.磁共振成像,2023,14(3):65-71. WANG Z,WU Q,NING N,et al.The value of mDixon-Quant technique in diagnosis and prognosis evaluation of breast invasive ductal carcinoma ［J］.Journal of Magnetic Resonance Imaging,2023,14(3):65-71.
［12］ 刘克,刘颖,屠英暄,等.乳腺浸润性导管癌不同分子分型及病理组织学分级间常规超声征像的差异［J］.武警医学,2021,32(7):607-611,615. LIU K,LIU Y,TU YX,et al.Difference of conventional ultrasonographic features in different molecular types and histopathological grades of invasive ductal carcinoma of breast ［J］.Chinese Journal of Armed Police Medicine,2021,32(7):607-611,615.
［13］ 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)［J］.中国癌症杂志,2021,31(10):954-1040. Breast Cancer Professional Committee of Chinese Anti-Cancer Association.Guidelines and norms for diagnosis and treatment of breast cancer of Chinese Anticancer Association (2021 edition)［J］.Chinese Journal of Cancer,2021,31(10):954-1040.
［14］ SINGLETARY SE,ALLRED C,ASHLEY P,et al.Revision of the American joint committee on cancer staging system for breast cancer［J］.Journal of Clinical Oncology,2002,20(17):3628-3636.
［15］ ADAMOVICH TL,SIMMONS RM.Ductal carcinoma in situ with microinvasion［J］.Am J Surg，2003,186(2):112,116.
［16］ KUERER HM,SMITH BD,CHAVEZ-MACGREGOR M,et al.DCIS Margins and breast conservation:MD anderson cancer center multidisciplinary practice guidelines and outcomes［J］.J Cancer，2017,8(14):2653-2662.
［17］ WANG G,ZHANG H,ZHANG Z,et al.Clinical and pathological characteristics of intraductal proliferative lesions and coexist with invasive ductal carcinomas［J］.Chinese Journal of Clinical Oncology:English,2013,12(12):574-580.
［18］ 冷盈.乳腺导管原位癌伴微浸润的临床特征及预后分析［D］.泸州：西南医科大学,2020. LENG Y.Clinical features and prognosis of ductal carcinoma in situ with microinfiltration of breast ［D］.Luzhou:Southwest Medical University,2020.
［19］ 聂晨蕾,易春蓓,巩海燕,等.乳腺导管内癌及导管内癌伴微浸润的临床、病理及超声特征对比研究［J］.中国肿瘤外科杂志,2020,12(1):32-36. NIE CL,YI CB,GONG HY,et al.Comparative study of clinical,pathologic and ultrasonic characteristics of intraductal carcinoma of breast and intraductal carcinoma with microinvasion ［J］.Chinese Journal of Surgical Oncology,2020,12(1):32-36.
［20］ 张晓丽,张彦宁,邱兰燕.乳腺导管原位癌及其微浸润的超声及临床病理对比研究［J］.医学研究杂志,2021,50(6):140-144. ZHANG XL,ZHANG YN,QIU LY.Ultrasound and clinicopathological comparison of ductal carcinoma in situ and microinfiltration of breast ［J］.Journal of Medical Research,2021,50(6):140-144.
［21］ WAN ZB,GAO HY,WEI L,et al.Expression of estrogen receptor,progesterone receptor,human epidermal growth factor receptor 2,and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion［J］.Medicine (Baltimore)，2018,97(44):e13055.
［22］ VIEIRA CC,MERCADO CL,CANGIARELLA J.Microinvasive ductal carcinoma in situ:clinical presentation,imaging features,pathologic findings,and outcome［J］.European Journal of Radiology,2010,73(1):102-107.
［23］ SAKR R,BARRANGER E,ANTOINE M,et al.Ductal carcinoma in situ:value of sentinel lymph node biopsy［J］.Journal of Surgical Oncology,2006,94(5):426-430.
［24］ D CRAIG ALLRED,STEWART J ANDERSON,SOONMYUNG PAIK,et al.Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ:A study based on NSABP protocol B-24［J］.Journal of Clinical Oncology,2012,30(12):1268-1273.
［25］ ZHANG W,GAO EL,ZHOU YL,et al.Different distribution of breast ductal carcinoma in situ,ductal carcinoma in situ with microinvasion,and invasion breast cancer［J］.World J Surg Oncol，2012,8(10):262.
［26］ WANG LI,ZHANG WEI,LYU SHUHUA,et al.Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast［J］.Tumour Biology:The Journal of the International Society for Oncodevelopmental Biology and Medicine,2015,36(4):2241-2248.
［27］ 郑杰.乳腺导管原位癌伴微小浸润的临床病理特征分析［D］.石家庄:河北医科大学,2019. ZHENG J.Clinicopathological characteristics of ductal carcinoma in situ with microinfiltration of breast ［D］.Shijiazhuang:Hebei Medical University,2019.
［28］ LIAO N,ZHANG GC,LIU YH,et al.HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component［J］.Pathology Research and Practice,2011,207(1):1-7.
［29］ KIM M,KIM HJ,CHUNG YR,et al.Microinvasive carcinoma versus ductal carcinoma in situ:A comparison of clinicopathological features and clinical outcomes［J］.J Breast Cancer，2018,21(2):197-205.
［30］ DANIELLE N MARGALIT,MEERA SREEDHARA,YU-HUI CHEN,et al.Microinvasive breast cancer:ER,PR,and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy［J］.Annals of Surgical Oncology,2013,20(3):811-818.
［31］ LATTA EK,TJAN S,PARKES RK,et al.The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast［J］.Modern Pathology,2002,15(12):1318-1325.
［32］ MENEZES MV,CESTARI AL,ALMEIDA O,et al.Protein expression of c-erbB-2 and p53 in normal ducts,ductal carcinoma in situ and invasive carcinoma of the same breast［J］.Sao Paulo Med J,2006,124(3):121-124.
［33］ PU T,ZHONG X,DENG L,et al.Long term prognosis of ductal carcinoma in situ with microinvasion:a retrospective cohort study［J］.Int J Clin Exp Pathol,2018,11(5):2665-2674.
［34］ 刘仪萱,姚峰.乳腺导管原位癌伴微浸润与浸润癌患者的临床特征对比分析［J］.现代肿瘤医学,2021,29(21):3766-3769. LIU YX,YAO F.Comparative analysis of clinical features of breast ductal carcinoma in situ with microinvasion and invasive carcinoma ［J］.Modern Oncology,2021,29(21):3766-3769.
［35］ 刘克,王胜林.乳腺浸润性导管癌的X光影像与分子分型及其组织学分级的相关性研究［J］.实用肿瘤学杂志,2021,35(2):148-153. LIU K,WANG SL.Study on the correlation between X-ray images and molecular classification and histological grade of invasive ductal carcinoma of breast ［J］.Journal of Practical Oncology,2021,35(2):148-153.
［36］ 张倩,宋蕾,侯金香,等.不同分子分型的非特殊型浸润性乳腺癌超声及钼靶特征分析［J］.中国医学装备,2020,17(7):70-74. ZHANG Q,SONG L,HOU JX,et al.Analysis of ultrasonic and molybdenum target characteristics of non-specific invasive breast cancer with different molecular types ［J］.Chinese Medical Equipment,2020,17(7):70-74.
［37］ 罗含欢,姜英,边巴扎西,等.西藏地区非特殊型浸润性乳腺癌雄激素受体的表达及其与不同分子分型及临床病理特征的相关性［J］.中国医学科学院学报,2022,44(6):1033-1039. LUO HH,JIANG Y,BIANBAZHAXI,et al.Expression of androgen receptor in non-specific invasive breast cancer in Tibet and its correlation with different molecular types and clinicopathological features ［J］.Journal of Chinese Academy of Medical Sciences,2022,44(6):1033-1039.
［38］ LIU BT,DING JN,WANG JL,et al.Differences in pathologic characteristics between ductal carcinoma in situ (DCIS),DCIS with microinvasion and DCIS with invasive ductal carcinoma［J］.Int J Clin Exp Pathol,2020,13(5):1066-1072.
［39］ SANG J,YI D,TANG X,et al.The associations between mast cell infiltration,clinical features and molecular types of invasive breast cancer［J］.Oncotarget,2016,7(49):81661-81669.
［40］ 汪玲,潘华锋,李琰.不同分子分型乳腺癌临床病理特征及预后分期分析［J］.临床外科杂志,2019,27(3):231-234. WANG L,PAN HF,LI Y.Analysis of clinicopathological features and prognostic staging of different molecular types of breast cancer ［J］.Journal of Clinical Surgery,2019,27(3):231-234.
［41］ 刘钟芬,陈创,姚晓莉,等.乳腺癌不同分子分型的临床病理特点及预后分析［J］.中华医学杂志,2016,96(22):1733-1737. LIU ZF,CHEN C,YAO XL,et al.Clinicopathological characteristics and prognosis of different molecular types of breast cancer ［J］.China Medical Journal,2016,96(22):1733-1737.

Memo

Memo:
-
Last Update: 2023-11-30